Target Audience (click to view)
This activity is designed to meet the needs of physicians.
Learning Objectives(click to view)
Upon completion of the educational activity, participants should be able to:
- Review key recommendations made in the American Society of Clinical Oncology’s 2014 clinical practice guideline adaptation on screening, assessment, and management of fatigue in adult survivors of cancer.
Method of Participation(click to view)
Statements of credit will be awarded based on the participant reviewing monograph, correctly answer 2 out of 3 questions on the post test, completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.akhcme.com/pwjune5. You must participate in the entire activity to receive credit. If you have questions about this CME/CE activity, please contact AKH Inc. at firstname.lastname@example.org.
Credit Available(click to view)
CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Physician’s Weekly’s. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support(click to view)
There is no commercial support for this activity.
Disclosures(click to view)
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
Disclosure of Unlabeled Use & Investigational Product(click to view)
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer(click to view)
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
Faculty & Credentials(click to view)
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
Dorothy Caputo, MA, BSN, RN- CE Director of Accreditation
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
AKH planners and reviewers have no relevant financial relationships to disclose.
Complete the Post Test(click to view)
With recent advances in cancer screening and treatment, the number of cancer survivors in the United States has increased substantially in recent years. The American Cancer Society estimates that there are about 13.7 million cancer survivors in the U.S., and this figure is expected to rise to nearly 18 million by 2022. Over the years, the Cancer Survivorship Committee of the American Society of Clinical Oncology (ASCO) has issued evidence-based clinical practice guidelines, assessment tools, and screening instruments to help identify and manage late effects of cancer and its treatment. Recently, ASCO released a guideline for managing survivors who experience symptoms of fatigue after completing primary cancer treatment.
The practice guideline pertains to cancer survivors diagnosed at age 18 or older who have completed treatment with curative intent and are in clinical remission without the need for therapy. It is also applicable to patients who are disease free and have transitioned to maintenance or prophylactic therapy. Examples of these patients include breast cancer survivors receiving hormonal therapy and people with chronic myelogenous leukemia receiving tyrosine kinase inhibitors. ASCO’s guidelines are intended to inform all members of patients’ healthcare team as well as patients, family members, and caregivers of cancer survivors.
Fatigue Is a Common Problem
“Many cancer survivors will experience some level of fatigue during their course of treatment,” explains Julienne E. Bower, PhD, who was co-chair of the ASCO writing group that developed the guidelines. “About 20% to 30% of cancer survivors deal with persistent fatigue for years after they’ve been treated for cancer. Fatigue is among the most common and distressing long-term effects of cancer treatment and negatively affects quality of life.”
Screen & Assess Patients for Fatigue
According to ASCO, all healthcare providers should routinely screen patients for the presence of fatigue from diagnosis onward. This includes the period after patients complete their primary treatment. “We need to screen all patients for fatigue after their cancer treatment ends,” says Dr. Bower. ASCO recommends that screening be performed and documented using a quantitative or semi-quantitative assessment and provides a list of helpful instruments that can be used.
The guidelines note that patients who report elevated fatigue on screening (scoring a 4 or greater on a 0 to 10 scale) should undergo more intensive fatigue-oriented assessment. Patient assessments should be a shared responsibility of the clinical team, according to the guidelines. When reviewing patient history and conducting physical exams, clinicians are recommended to perform a focused fatigue history and evaluate patients for their disease status as well as treatable contributing factors. Together, the clinical team should decide when referrals to appropriately trained professionals are warranted. A laboratory evaluation should be considered based on the presence of other symptoms and on the onset and severity of fatigue.
Fatigue Management: Treatment Strategies
With regard to treatment, the ASCO guidelines recommend that all patients receive education about fatigue and general strategies for fatigue management (Table). “Initiating and maintaining adequate levels of physical activity may be particularly important,” says Dr. Bower. “Physical activity can reduce cancer-related fatigue after treatment.” Clinicians should also address other medical and treatable contributing factors, such as pain, depression, anxiety, and other comorbidities.
For patients with severe or persistent fatigue, the ASCO guidelines offer recommendations on psychosocial, mind-body, and pharmacologic interventions. Several psychosocial interventions can be of benefit to this patient group, including cognitive behavioral therapy and psycho-educational therapy. “There is also evidence that mindfulness-based approaches, such as yoga, acupuncture, and other interventions, may reduce fatigue in cancer survivors,” says Dr. Bower. With regard to pharmacologic interventions, there is evidence that psychostimulants and other wakefulness agents can help manage fatigue in advanced cancer patients receiving active treatment, but there is limited evidence of their effectiveness in reducing fatigue in disease-free individuals who have completed treatment.
Tailor Approaches for Post-Treatment Fatigue
Follow-up care for cancer survivors is often challenging, especially if patients are dealing with comorbidities and receiving care from multiple providers. “Considering that multiple factors contribute to post-treatment fatigue, interventions should be tailored to each patient’s specific needs based on their type of cancer, treatments received, overall health, and personal preferences,” Dr. Bower says. In particular, several non-pharmacologic treatment approaches have been effective for cancer survivors in clinical research. Care should also be coordinated during transitions to primary care providers or survivorship clinics. “With open communication, we can decrease the burden of fatigue among cancer survivors,” says Dr. Bower. “We can also optimize decisions when determining appropriate management strategies.”
Readings & Resources (click to view)
Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Onc. 2014 Apr 14 [Epub ahead of print]. Available at: http://jco.ascopubs.org/content/early/2014/04/09/JCO.2013.53.4495.abstract.
Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18:743-753.
Mitchell SA, Beck SL, Hood LE, et al. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs. 2007;11:99-113.
Puetz TW, Herring MP. Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. Am J Prev Med. 2012;43:e1-e24.
Yun YH, Lee KS, Kim YW, et al: Web-based tailored education program for disease-free cancer survivors with cancer-related fatigue: a randomized controlled trial. J Clin Oncol. 2012;30:1296-1303.